(S)-(-)-Sulpiride
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H562057

CAS#: 23672-07-3

Description: (S)-(-)-Sulpiride selective D2-like dopamine antagonist.

Chemical Structure

img
(S)-(-)-Sulpiride
CAS# 23672-07-3
Instruction

Theoretical Analysis

Hodoodo Cat#: H562057
Name: (S)-(-)-Sulpiride
CAS#: 23672-07-3
Chemical Formula: C15H23N3O4S
Exact Mass: 341.14
Molecular Weight: 341.420
Elemental Analysis: C, 52.77; H, 6.79; N, 12.31; O, 18.74; S, 9.39

Price and Availability

Size Price Availability Quantity
5g USD 300 2 Weeks
10g USD 550 2 Weeks
Bulk inquiry

Synonym: (S)-(-)-Sulpiride;Levosulpiride; Nexipride; RV12309; RV 12309; RV-12309

IUPAC/Chemical Name: (S)-(-)-5-Aminosulfonyl-N-[(1-ethyl-2-pyrrolidinyl)methyl]-2-methoxybenzamide

InChi Key: BGRJTUBHPOOWDU-NSHDSACASA-N

InChi Code: InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)/t11-/m0/s1

SMILES Code: O=C(NC[C@H]1N(CC)CCC1)C2=CC(S(=O)(N)=O)=CC=C2OC

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 341.42 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Bryan EJ, Purcell MA, Kumar A. Zuclopenthixol dihydrochloride for schizophrenia. Cochrane Database Syst Rev. 2017 Nov 16;11:CD005474. doi: 10.1002/14651858.CD005474.pub2. Review. PubMed PMID: 29144549.

2: Sampford JR, Sampson S, Li BG, Zhao S, Xia J, Furtado VA. Fluphenazine (oral) versus atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2016 Jul 2;7:CD010832. doi: 10.1002/14651858.CD010832.pub2. Review. PubMed PMID: 27370402.

3: Lopez Vicchi F, Luque GM, Brie B, Nogueira JP, Garcia Tornadu I, Becu-Villalobos D. Dopaminergic drugs in type 2 diabetes and glucose homeostasis. Pharmacol Res. 2016 Jul;109:74-80. doi: 10.1016/j.phrs.2015.12.029. Epub 2015 Dec 31. Review. PubMed PMID: 26748034.

4: Banzi R, Cusi C, Randazzo C, Sterzi R, Tedesco D, Moja L. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults. Cochrane Database Syst Rev. 2015 May 1;(5):CD011681. doi: 10.1002/14651858.CD011681. Review. PubMed PMID: 25931277.

5: Leucht S, Winter-van Rossum I, Heres S, Arango C, Fleischhacker WW, Glenthøj B, Leboyer M, Leweke FM, Lewis S, McGuire P, Meyer-Lindenberg A, Rujescu D, Kapur S, Kahn RS, Sommer IE. The optimization of treatment and management of schizophrenia in Europe (OPTiMiSE) trial: rationale for its methodology and a review of the effectiveness of switching antipsychotics. Schizophr Bull. 2015 May;41(3):549-58. doi: 10.1093/schbul/sbv019. Epub 2015 Mar 18. Review. PubMed PMID: 25786408; PubMed Central PMCID: PMC4393704.

6: McLoughlin BC, Pushpa-Rajah JA, Gillies D, Rathbone J, Variend H, Kalakouti E, Kyprianou K. Cannabis and schizophrenia. Cochrane Database Syst Rev. 2014 Oct 14;(10):CD004837. doi: 10.1002/14651858.CD004837.pub3. Review. PubMed PMID: 25314586.

7: Wang J, Sampson S. Sulpiride versus placebo for schizophrenia. Cochrane Database Syst Rev. 2014 Apr 11;(4):CD007811. doi: 10.1002/14651858.CD007811.pub2. Review. PubMed PMID: 24729184.

8: Janssen P, Harris MS, Jones M, Masaoka T, Farré R, Törnblom H, Van Oudenhove L, Simrén M, Tack J. The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis. Am J Gastroenterol. 2013 Sep;108(9):1382-91. doi: 10.1038/ajg.2013.118. Review. PubMed PMID: 24005344.

9: Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA; American Academy of Neurology. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013 Jul 30;81(5):463-9. doi: 10.1212/WNL.0b013e31829d86b6. Review. Erratum in: Neurology. 2013 Nov 26;81(22):1968. PubMed PMID: 23897874.

10: Danilov DS. [Possibilities in using sulpiride in the treatment of psychotic disorders]. Zh Nevrol Psikhiatr Im S S Korsakova. 2012;112(6):91-7. Review. Russian. PubMed PMID: 22983256.

11: Kishi T, Kafantaris V, Sunday S, Sheridan EM, Correll CU. Are antipsychotics effective for the treatment of anorexia nervosa? Results from a systematic review and meta-analysis. J Clin Psychiatry. 2012 Jun;73(6):e757-66. doi: 10.4088/JCP.12r07691. Review. PubMed PMID: 22795216.

12: Leung K. (R)-2-[(11)C]Methoxy-N-n-propylnorapomorphine. 2006 Apr 11 [updated 2012 Feb 1]. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from http://www.ncbi.nlm.nih.gov/books/NBK23684/ PubMed PMID: 20641879.

13: Leung K. N-(4-(4-(2-(2-[(18)F]Fluoroethoxy)phenyl)piperazine-1-yl)butyl)-4-(3-thienyl)benz amide. 2011 Jun 24 [updated 2011 Oct 6]. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from http://www.ncbi.nlm.nih.gov/books/NBK65019/ PubMed PMID: 21994970.

14: Leung K. [(11)C](+)-4-N-Propyl-,3,4a,5,6,10b-hexahydro-2H-naphth[1,2-b][1,4]-oxazin-9-ol. 2006 May 2 [updated 2011 Oct 6]. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from http://www.ncbi.nlm.nih.gov/books/NBK23408/ PubMed PMID: 20641608.

15: Leung K. (S)-N-(1-Ethyl-2-pyrrolidinyl)methyl)-5-bromo-2-[(11)C]methoxy-3-methoxybenzamide . 2006 Apr 11 [updated 2011 Oct 6]. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from http://www.ncbi.nlm.nih.gov/books/NBK22980/ PubMed PMID: 20641188.

16: Leung K. (-)-N-[(11)C]Propyl-norapomorphine. 2006 Apr 6 [updated 2011 Jun 30]. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from http://www.ncbi.nlm.nih.gov/books/NBK23195/ PubMed PMID: 20641398.

17: Sommer IE, Begemann MJ, Temmerman A, Leucht S. Pharmacological augmentation strategies for schizophrenia patients with insufficient response to clozapine: a quantitative literature review. Schizophr Bull. 2012 Sep;38(5):1003-11. doi: 10.1093/schbul/sbr004. Epub 2011 Mar 21. Review. PubMed PMID: 21422107; PubMed Central PMCID: PMC3446238.

18: Leung K. (R)-(-)-2-Chloro-N-[1-(11)C-propyl]n-propylnorapomorphine. 2010 Oct 24 [updated 2010 Dec 11]. Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. Available from http://www.ncbi.nlm.nih.gov/books/NBK50682/ PubMed PMID: 21204317.

19: Chen J, Gao K, Kemp DE. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr Opin Psychiatry. 2011 Jan;24(1):10-7. doi: 10.1097/YCO.0b013e3283413505. Review. PubMed PMID: 21088586.

20: Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, Kissling W, Davis JM, Leucht S. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010 Nov;123(2-3):225-33. doi: 10.1016/j.schres.2010.07.012. Epub 2010 Aug 7. Review. PubMed PMID: 20692814; PubMed Central PMCID: PMC2957510.